Edition: United Kingdom  
One News Page
“Probably the fastest-access news portal in the world”
> >

FDA Experts Endorse Pioneering New Gene Therapy Treatment For Blindness

Duration: 00:41s - Published: < > Embed
News video: FDA Experts Endorse Pioneering New Gene Therapy Treatment For BlindnessA new ground-breaking gene therapy from Spark Therapeutics took a huge step towards FDA approval yesterday as a panel of experts offered their support for getting the treatment into the market. The vote was 16 to 0 favoring the benefit-risk profile of the drug, providing a compelling reason for the US FDA to approve the first US vector-delivered gene therapy.

0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

Recent related news

New gene therapy gives hope to people born with inherited eye disorder

New gene therapy gives hope to people born with inherited eye disorderriggleton/Shutterstock The first successful gene therapy for an inherited form of blindness was...
WorldNews - Front Page

New gene therapy treatment could hit $1M per patient because of additional costs

The costs of using a new class of cancer treatments include far more than the drug’s sticker...
USATODAY.com - Front Page

U.S. FDA finds Spark's blindness treatment initially effective

(Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness...
Reuters - Health

FDA panel backs gene therapy for rare form of blindness

(Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare form of blindness improves...
Reuters - Health

Spark's blindness gene therapy reviewed by U.S. FDA

(Reuters) - Spark Therapeutics Inc's experimental gene therapy for a rare inherited form of blindness...
Reuters - Health

Exelixis shares soar on news FDA grants priority review to its kidney cancer drug

Biotech Exelixis Inc. (NASDAQ:EXEL) saw its shares surge in premarket trade on Monday after the U.S....
Proactive Investors - Business

GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985,...
Business Wire - Press Releases

Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell CarcinomaSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that the...
Business Wire - Press Releases


You Might Like

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+